| Date | Title | Description |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 16.03.2017 | Glimmers of hope for science & healthcare in the punishing budget blueprint | An ominous gray cloud drifted over science on Thursday, with the release of the Trump administration’s blueprint for Federal spending in 2018.
The draft budget outlines unexpectedly brutal cuts to medical research and healthcare.
At the hig... |
| 12.05.2015 | Pharma company’s app supports treatment for opioid abuse | It reasons that most people have a mobile phone so having an app as an access point is the easiest way to reach patients.
“What we’re trying to do is offer physicians a different type of patient support,” Medwar said. Treatment centers are ... |
| 27.02.2013 | 4 life sciences CEOs on lessons learned the hard way | Tim Willis, president, CEO and co-founder, TearScience: “We were out raising a series C, and we thought we had done our due diligence on the firms we were working with, and we assumed incorrectly that they had money to (do deals). I had fou... |
| 21.05.2012 | BDSI’s cancer pain product preps for Europe, triggers $2.5M milestone | The U.S. Food and Drug Administration approved Onsolis in 2009, though the product has experienced slow U.S. sales since. The FDA put the product under a Risk Evaluation and Mitigation Strategy, or REMS, which imposes stricter requirements ... |
| 17.04.2012 | Patent award to BDSI triggers $15M milestone payment from Endo Pharma | The USPTO had signaled earlier this year that it would issue a patent for the technology. In February, the patent office issued a notice of allowance, which means that a review found the application meets all the requirements for a patent.
... |
| 12.03.2012 | FDA concerns delay relaunch of BDSI cancer pain product Onsolis | “They’re strictly related to the appearance of the product,” BDSI vice president of marketing Al Medwar said of the changes. “There’s no efficacy or safety issue.”
Onsolis that is currently on the market can continue to be used for cancer p... |
| 16.02.2012 | BDSI to get patent; issuance triggers $15M milestone from partner Endo | The milestone payment will be coming from drug partner Endo Pharmaceuticals (NASDAQ:ENDP). Raleigh, North Carolina-based BDSI and Endo last month entered a development and commercialization deal that could pay BDSI up to $180 million upon s... |
| 06.02.2012 | $40M stock offering filed by BioDelivery Sciences International | The Endo deal, which gave BDSI $30 million up front, secures a partner responsible for the phase 3 trials and commercialization of BEMA Buprenorphine. That frees BDSI to devote its attention and its financial resources to the rest of its dr... |
| 06.01.2012 | Chronic pain treatment from BDSI licensed to Endo Pharma in $180M deal | “Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain,” Endo CEO Dave Holveck said in a statement.
BEMA Buprenorphine utilizes BDSI’s propri... |
| 30.12.2011 | How FDA changes to ‘REMS’ rules helps BioDelivery Sciences | Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration plans to manage possible health risks. The FDA is changing how it manages these drugs and these changes should help Raleigh, North Carolina co... |
| 15.11.2011 | BDSI needs partner to finance round 2 of phase 3 trials in chronic pain | BioDelivery Sciences International (NASDAQ:BDSI) is running low on cash and running short on time as it works to find a drug partner before it runs out of both.
The company has $15.1 million in cash — enough to last through the second quart... |
| 29.09.2011 | BDSI: Pharma partners still interested in pain drug’s $500M potential | “When you look across the pain category, this represents one of the few opportunities of this magnitude,” Sirgo said.
Raleigh, North Carolina-based BDSI has not yet discussed the latest results with the prospective drug partners. Partnering... |
| 28.09.2011 | BDSI pain drug fails in phase 3 trials but company plans new study | Investors saw otherwise and BDSI’s stock price plunged more than 39 percent to $1.85 in after hours trading.
BEMA Buprenorphine missed its first clinical trial target: an overall pain intensity difference between the BDSI drug and a placebo... |
| 06.09.2011 | BDSI’s opioid-addiction drug candidate aims to challenge market leader RB | “If the results from this pivotal study are positive, we could be in a position to submit a New Drug Application (NDA) for BEMA buprenorphine/naloxone in the second half of 2012,” Dr. Andrew Finn, BDSI’s executive vice president of product ... |
| 22.08.2011 | BDSI’s cancer pain treatment Onsolis now slated for 3Q Canada launch | But problems at the site of the contract manufacturer have delayed Onsolis’ Canada launch three times. BDSI now says enough Onsolis has been produced to avoid shortages in the United States and supply sufficient product for a Canada launch.... |
| 08.06.2011 | FDA’s REMS program puts BDSI at a disadvantage in cancer drug market | BDSI has been working with the FDA on changes to get its lead product on the same footing as its competitors. While BDSI had hoped to finish those changes in the second quarter, now it looks like it will be a little bit longer. Vice preside... |
| 21.03.2011 | NC pharma BioDelivery Sciences gets patent extension in Canada | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| - | BDSI needs partner to finance round 2 of phase 3 trials in chronic pain | BioDelivery Sciences International (NASDAQ:BDSI) is running low on cash and running short on time as it works to find a drug partner before it runs out of both.
The company has $15.1 million in cash — enough to last through the second quart... |
| - | $40M stock offering filed by BioDelivery Sciences International | A month after licensing a clinical-stage chronic pain treatment to Endo Pharmaceuticals (NASDAQ:ENDP) in a deal worth up to $180 million, BioDelivery Sciences International (NASDAQ: BDSI) is now preparing an additional $40 million financial... |
| - | How FDA changes to ‘REMS’ rules helps BioDelivery Sciences | Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration plans to manage possible health risks. The FDA is changing how it manages these drugs and these changes should help Raleigh, North Carolina co... |
| - | 4 life sciences CEOs on lessons learned the hard way | There are some lessons that no amount of reading can teach an entrepreneur. Sometimes, you just have to learn by doing.
And that goes for companies at all stages, as a panel of CEOs at the CED Life Science Conference shared on Wednesday. Du... |
| - | Chronic pain treatment from BDSI licensed to Endo Pharma in $180M deal | The investigational chronic pain treatment from BioDelivery Sciences International (NASDAQ:BDSI) that failed in a late-stage clinical trial now has a partner and a plan that salvages the drug program and infuses the biopharmaceutical compan... |
| - | BDSI’s cancer pain treatment Onsolis now slated for 3Q Canada launch | BioDelivery Sciences International‘s (NASDAQ:BDSI) treatment for breakthrough cancer pain is now slated to launch in Canada this quarter – more than a year after the company had initially planned its Canada launch.
Raleigh, North Carolina-b... |
| - | Pharma company’s app supports treatment for opioid abuse | Many of the apps that pharma companies are developing to support conditions or specific drugs and diagnostics are either only available outside the U.S. or are still being evaluated in pilot studies. A specialist drug developer rolled out a... |
| - | NC pharma BioDelivery Sciences gets patent extension in Canada | North Carolina pharmaceutical company BioDelivery Sciences International has extended its patent in Canada by 10 years, giving additional protection for the company’s core drug delivery technology.
Raleigh, North Carolina based BDSI’s (NASD... |
| - | Glimmers of hope for science & healthcare in the punishing budget blueprint | An ominous gray cloud drifted over science on Thursday, with the release of the Trump administration’s blueprint for Federal spending in 2018.
The draft budget outlines unexpectedly brutal cuts to medical research and healthcare.
At the hig... |
| - | BDSI’s opioid-addiction drug candidate aims to challenge market leader RB | An opioid-dependence treatment being developed by BioDelivery Sciences International (NASDAQ:BDSI) is on track for a New Drug Application filing in the second half of 2012, making it a contender to compete against current market leader Reck... |
| - | BDSI: Pharma partners still interested in pain drug’s $500M potential | Before BioDelivery Sciences International (NASDAQ:BDSI) released early phase 3 clinical trial results showing its pain drug missed the primary target of its study, the company had gotten as far as term sheets and draft definitive agreements... |
| - | BDSI’s cancer pain product preps for Europe, triggers $2.5M milestone | The breakthrough cancer pain treatment developed by BioDelivery Sciences (NASDAQ:BDSI) International is making progress toward entering the European market, triggering a $2.5 milestone payment from BDSI’s drug partner Meda Pharmaceuticals.
... |
| - | Patent award to BDSI triggers $15M milestone payment from Endo Pharma | A drug delivery technology patent awarded to BioDelivery Sciences International (NASDAQ:BDSI) has triggered a $15 million milestone payment from drug partner Endo Pharmaceuticals (NASDAQ:ENDP).
Raleigh, North Carolina-based BDSI said today ... |
| - | FDA concerns delay relaunch of BDSI cancer pain product Onsolis | Plans to relaunch breakthrough cancer pain treatment Onsolis are now delayed indefinitely until BioDelivery Sciences International (NASDAQ:BDSI) can work out manufacturing issues raised by the U.S. Food and Drug Administration.
Over Onsolis... |
| - | BDSI to get patent; issuance triggers $15M milestone from partner Endo | BioDelivery Sciences International (NASDAQ:BDSI) stands to gain a $15 million milestone payment after getting word that its drug delivery technology will be granted a patent for two drug treatments.
The U.S. Patent and Trademark Office has ... |
| - | FDA’s REMS program puts BDSI at a disadvantage in cancer drug market | Commercializing a new drug in the face of strict U.S. Food and Drug Administration guidelines is tough. It’s even tougher when direct competitors don’t have those same limits.
That’s the situation facing Raleigh, North Carolina-based BioDel... |
| - | BDSI pain drug fails in phase 3 trials but company plans new study | A pain drug candidate from BioDelivery Sciences International (NASDAQ:BDSI) failed to perform better than a placebo in phase 3 clinical trials, according to preliminary trial results released by the biopharmaceutical company after the close... |
